Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE0005664809
Tue, 12.05.2026
Evotec SE
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR IN ANY OTHER JURISDICTION IN WHICH, OR TO PERSONS IN ANY JURISDICTION TO WHOM, SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAW.
Evotec SE Successfully Placed €116.1 Million Convertible Bon [ … ]
Tue, 12.05.2026
Evotec SE
Disclosure of inside information pursuant to Article 17 MAR
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL
Evotec SE launches approximately EUR 125 million convertible bond offering
Hamburg, Germany, 1 [ … ]
Wed, 06.05.2026
Evotec SE
Evotec Announces First Quarter 2026 Results: Building Transformation Momentum
Q1 2026 financial performance: Full-year 2026 guidance confirmed; start to the year as expected with group revenues of €156.6 m (€166.9 m at CER); adj. Group EBITDA of -€21.9 m (-€18.9 m at CER) impacted by one-off effects and foreign exchange headwinds
D&PD partn [ … ]
Mon, 04.05.2026
Evotec SE
Joint Evotec–Almirall team advances small molecule program to preclinical development significantly outperforming standard industry timelines
Collaboration leverages Evotec’s end-to-end integrated AI/ML-driven R&D capabilities and Almirall’s dermatology expertise
Hamburg, Germany, May 4, 2026 – Evotec SE (NASDAQ: EVO; Fran [ … ]
Thu, 30.04.2026
Evotec SE
Grants support discovery and development of novel drug candidates and evaluation and prioritization of advanced drug regimens for clinical testing
New funding from the Gates Foundation extends Evotec’s commitment to create more effective tuberculosis treatment regimens
Hamburg, Germany, April 30, 2026 – Evotec SE (NASDAQ: EVO; [ … ]
Wed, 29.04.2026
Evotec SE
Evotec Announces New Nomination to Board of Directors
Nomination of Dr. Wolfgang Hofmann as independent Supervisory Board member to further strengthen oversight and governance capabilities
Conclusion of cooperation agreement with MAK Capital following constructive discussions, reflecting Evotec’s commitment to open shareholder dialogue
Annual Ge [ … ]
Fri, 24.04.2026
Evotec SE
Paul Hitchin to step down as of April 30, 2026
Claire Hinshelwood appointed to CFO role as of May 1, 2026
Hamburg, Germany, April 24, 2026 – Evotec SE (NASDAQ: EVO; Frankfurt Prime Standard: EVT) today announced that Chief Financial Officer (CFO) Paul Hitchin will step down on April 30, 2026, for personal reasons unrelated to [ … ]
Wed, 08.04.2026
Evotec SE
Evotec Announces Fourth Quarter and Full-Year 2025 Results: Foundation for Profitable Growth
2025 financial performance at high end of guidance: Q4 and FY group revenues of €253.3 m and €788.4 m, respectively (Q4: €266.7 m, FY: €810.4 m at CER); adj. group EBITDA of €58.0 m and €41.1 m, respectively (Q4: €64.8 m, FY: €52.3 m at CER)
Robust exec [ … ]
Tue, 07.04.2026
Evotec SE
Evotec Nominates Dieter Weinand as Supervisory Board Chairman
Strengthens Supervisory Board leadership to support Evotec’s transformation, with a focus on commercial execution, strategic partnerships and profitability
Industry veteran brings more than 30 years of global pharmaceutical industry leadership experience across senior management, comm [ … ]
Wed, 01.04.2026
Evotec SE
Hamburg, Germany, April 1, 2026 – Evotec SE (NASDAQ: EVO; Frankfurt Prime Standard: EVT) will hold a webcast and conference call to announce its financial results for the fourth quarter and full-year 2025 and provide a business update on Wednesday, April 8, 2026. The conference call will be held in English.
Webcast details
Date: Wednesday, April [ … ]
